Artiva Biotherapeutics (ARTV) Receivables - Net (2023 - 2024)

Artiva Biotherapeutics' (ARTV) quarterly Receivables - Net came in at $569000.0 in Q3 2024, little changed on a QoQ basis from $569000.0 in Q2 2024.

Artiva Biotherapeutics (ARTV) Receivables - Net (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has 2 years of Receivables - Net data on file, last reported at $569000.0 in Q3 2024.

On a quarterly basis, Receivables - Net changed N/A year-over-year to $569000.0 in Q3 2024; TTM through Sep 2024 was $569000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $1.0 million, changed N/A from the prior year.
Receivables - Net for Q3 2024 stood at $569000.0, roughly flat from $569000.0 in the prior quarter.
Over the last five years, Receivables - Net for ARTV reached as high as $1.0 million in Q4 2023 and fell as low as $569000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Artiva Biotherapeutics	249.99 Mn	249.99 Mn	-

Download Data